TGEN - Targeted Genetics Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation

TGEN 8.005

-1.3%

2:22 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (452)	12/9/2005 10:54:11 AM
From: 9wald9	of 557

CELLADON SECURES 30 MILLION IN SERIES B FINANCING 12/07/2005 Newswire PR in part: "This financing will support development of Celladon's MYDICAR(TM) gene therapy system, which enhances SERCA2a, an important regulator of myocardial contractility," said Krisztina Zsebo, Celladon's CEO. The SERCA2a gene construct is inserted in Adeno-Associated Virus (AAV) vectors and delivered to the heart percutaneously using a closed-loop oxygenated system. Celladon Corporation is collaborating with Targeted Genetics Corporation [TGEN] on AAV-based manufacturing and gene product development; and with The Baker Heart Research Institute and V-Kardia, Inc. in development of a percutaneous delivery system.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next